SYRS - Syros Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.79
+0.19 (+2.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close8.60
Open8.78
Bid8.68 x 800
Ask9.50 x 1200
Day's Range8.68 - 9.23
52 Week Range4.26 - 11.93
Volume289,206
Avg. Volume349,673
Market Cap401.643M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.95
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program
    Business Wire

    Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data show that SY-5609 inhibits tumor growth, including inducing sustained regressions, at well-tolerated doses in colorectal cancer models, supporting the inclusion of colorectal cancer patients in Syros’ ongoing Phase 1 clinical trial. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20).

  • Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
    PR Newswire

    Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.

  • Top Ranked Momentum Stocks to Buy for May 19th
    Zacks

    Top Ranked Momentum Stocks to Buy for May 19th

    Top Ranked Momentum Stocks to Buy for May 19th

  • Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program
    Business Wire

    Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in models of colorectal cancer. These data will be presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) taking place May 29-31. Syros will also present on the design of its ongoing Phase 1 trial of SY-5609 at ASCO20.

  • Industry Analysts Just Upgraded Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Revenue Forecasts By 20%
    Simply Wall St.

    Industry Analysts Just Upgraded Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Revenue Forecasts By 20%

    Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shareholders will have a reason to smile today, with the analysts making...

  • Syros Pharmaceuticals, Inc.(SYRS) Q1 2020 Earnings Call Transcript
    Motley Fool

    Syros Pharmaceuticals, Inc.(SYRS) Q1 2020 Earnings Call Transcript

    Image source: The Motley Fool. Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)Q1 2020 Earnings CallMay 07, 2020, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning and welcome to Syros Pharmaceuticals' first-quarter 2020 financial fesults conference call.

  • Benzinga

    Recap: Syros Pharmaceuticals Q1 Earnings

    Shares of Syros Pharmaceuticals (NASDAQ:SYRS) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 20.41% over the past year to ($0.39), which beat the estimate of ($0.43).Revenue of $2,379,000 rose by 424.01% year over year, which beat the estimate of $1,620,000.Guidance Syros Pharmaceuticals hasn't issued any earnings guidance for the time being.Syros Pharmaceuticals hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 07, 2020View more earnings on SYRSTime: 08:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/22t7kmbhPrice Action 52-week high: $11.93Company's 52-week low was at $4.26Price action over last quarter: Up 37.07%Company Description Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. The Company operates only in the United States.See more from Benzinga * Houghton Mifflin Harcourt: Q1 Earnings Insights * Autolus Therapeutics: Q1 Earnings Insights * World Acceptance: Q4 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
    Business Wire

    Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2020 and provided an update on recent accomplishments and upcoming events.

  • Volatility 101: Should Syros Pharmaceuticals (NASDAQ:SYRS) Shares Have Dropped 37%?
    Simply Wall St.

    Volatility 101: Should Syros Pharmaceuticals (NASDAQ:SYRS) Shares Have Dropped 37%?

    Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shareholders should be happy to see the share price up 27% in the last...

  • Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
    Business Wire

    Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a corporate update.

  • Billionaire Steven Cohen Picks up These 2 Stocks on the Dip
    TipRanks

    Billionaire Steven Cohen Picks up These 2 Stocks on the Dip

    Stocks roared higher on Monday, but one legendary hedge fund manager isn’t breaking out the champagne just yet. Optimism that COVID-19's spread may be slowing powered the market’s impressive rally, with the Dow Jones closing the session up by over 1,600 points. That said, it may be too early to start toasting to the market’s recovery and the end of dramatic volatility.Billionaire Steve Cohen is warning staff of his investment firm, Point72 Asset Management, to stay cautious as stocks rebound from the COVID-19-driven sell-off. “Markets don’t come back in a straight line; after an earthquake there are tremors... We need to continue to be disciplined. We are seeing plenty of opportunities to generate returns, but I don’t want us taking undue risks,” he wrote in an internal note.The Point72 Chairman and CEO has earned a reputation as one of the most successful stock pickers, with his firm relying on a core hedge fund strategy that features stock market investments. Less frequently, Point72, which is based in Stamford, Connecticut, will make plays based on macro trends, placing global wagers on several asset classes at the same time. With Cohen earning an estimated $1.3 billion in 2019 after the firm’s main hedge fund posted a 14.9% gain, it’s no wonder market watchers follow his moves religiously.Taking all of this into consideration, we used TipRanks’ database to take a closer look at two stocks Cohen snapped up recently on the dip. The platform revealed that both Buy-rated tickers have earned the support of some members of the analyst community as well.Calithera Bio (CALA)Calithera Bio uses a onco-metabolism approach that brings a unique perspective to cancer, with it developing small molecule therapies that disrupt cellular metabolic pathways to block tumor growth. While shares have fallen 17% year-to-date to reach $4.74 apiece, this price tag could be an ideal entry point for those looking to get in on the action.This is the stance taken by Steve Cohen. According to a March 13 disclosure, Point72 added a CALA holding to its portfolio, in the shape of 3,240,046 shares. As a result, Cohen’s firm now has a 5% stake in the healthcare company.Weighing in on CALA for Jeffries, analyst Biren Amin sees an opportunity as well. He notes that a significant component of his bullish thesis is its CB-839 candidate. There is a substantial unmet need for successful outcomes in second- and third-line renal cell carcinoma (RCC) as checkpoint inhibitors are designated for first line use. As the candidate has already demonstrated efficacy in RCC, the top-line data readout in the second half of 2020 could serve as a key catalyst. Not to mention Amin estimates peak U.S. sales of $21 million for RCC alone.Adding to the good news, CB-839 could potentially be used to treat non-small-cell lung cancer (NSCLC) patients with KEAP1/NRF2 mutations. “With no currently approved therapies for this patient sub-group, CB-839 has the potential to be first-to-market in this 13,000 patient population (recall, KRAS G12c is ~14,000 NSCLC)…We estimate peak U.S. sales for CB-839 of $204 million (risk adj) for KEAP1/ NRF2 mutant NSCLC,” Amin commented.With the analyst pointing out that its two arginase inhibitors in development, INCB001158 as part of a collaboration with Incyte and CB-280, stand to drive additional upside, it makes sense that Amin takes a bullish approach.All in all, the five-star analyst puts a Buy rating on Calithera shares along with a $6 price target. Should the target be met, a twelve-month gain of 27% could be in store. (To watch Amin’s track record, click here)Like the Jeffries analyst, the rest of the Street is bullish on CALA. 4 Buy ratings compared to no Holds or Sells add up to a Strong Buy consensus rating. At $6.67, the average price target is more aggressive than Amin’s and implies upside potential of 41%. (See Calithera stock analysis on TipRanks)Syros Pharmaceuticals (SYRS)With the goal of taking control of gene expression, Syros develops small molecules to help improve the lives of patients. March definitely wasn’t its month, but some members of the Street believe its long-term growth prospects are strong.Cohen falls into this category. Made public on April 2, Point72 pulled the trigger on this healthcare stock. Acquiring a new holding, its purchase of 2.3 million shares puts the firm’s total stake in SYRS at 5.1%.Turning now to the analyst community, Roth Capital’s Zegbeh Jallah told investors that SYRS’s fourth quarter earnings results demonstrate the company’s potential. “We believe that Syros has made steady progress over 2019, and we look forward to the multiple data readouts expected during, particularly the readout of SY-1425 in r/r AML which should be a major catalyst. Cash and cash equivalents are expected to be sufficient to fund operations beyond major catalysts, and into 2022,” he explained.During the quarter, the company released data for its lead candidate, SY-1425, a selective RARα agonist currently in a Phase 2 clinical study in patients with acute myeloid leukemia (AML). The therapy was not only able to show a 62% CR/CRi rate and an 82% rate of transfusion independence, but it also produced a fast onset of action, was tolerable as a combination with Azacitidine and validated the biomarker strategy for patient selection.“The focus will likely be on response durability, which will probably be extrapolated to gauge the potential for durable responses in the r/r AML setting, for which Syros hopes to pursue an accelerated regulatory pathway,” Jallah added.On top of this, proof-of-concept data from the Phase 2 study of SY-1425 and Aza in r/r AML, which is slated for release in the fourth quarter of 2020, could drive significant growth for the company. Jallah is also watching out for an update on initial PK/PD and safety data from the Phase 1 study of SY-5609, its first oral and noncovalent CDK7 inhibitor.Bearing this in mind, Jallah has high hopes for SYRS. Along with a Buy rating, the analyst left a $17 price target on the stock, indicating 146% upside potential. (To watch Jallah’s track record, click here)Looking at the consensus breakdown, opinions are split evenly down the middle. With 2 Buys and 2 Holds received in the last three months, the word on the Street is that SYRS is a Moderate Buy. Based on the $9.33 average price target, the upside potential comes in at 35%. (See Syros stock analysis on TipRanks)

  • Thomson Reuters StreetEvents

    Edited Transcript of SYRS earnings conference call or presentation 5-Mar-20 1:30pm GMT

    Q4 2019 Syros Pharmaceuticals Inc Earnings Call

  • Does Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Have A High Beta?
    Simply Wall St.

    Does Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Have A High Beta?

    Anyone researching Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) might want to consider the historical volatility of the...

  • Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
    Business Wire

    Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

    Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended December 31, 2019, and provided an update on recent accomplishments and upcoming events.

  • Here's Why We're Watching Syros Pharmaceuticals's (NASDAQ:SYRS) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching Syros Pharmaceuticals's (NASDAQ:SYRS) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • Is Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Paid At A Competitive Rate?
    Simply Wall St.

    Is Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Paid At A Competitive Rate?

    Nancy Simonian has been the CEO of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) since 2012. This report will, first...

  • Fresh off first sickle cell drug approval, Global Blood strikes new deals
    American City Business Journals

    Fresh off first sickle cell drug approval, Global Blood strikes new deals

    In the wake of its FDA nod, the South City company has lined up a $150 million loan agreement and, separately, a potential $375 million partnership with Syros Pharmaceuticals.

  • Flagship Unveils Newest Pioneering Platform: Ring Therapeutics
    PR Newswire

    Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

    Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

  • GlobeNewswire

    GBT Secures $150 Million Non-Dilutive Term Loan Financing

    Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that it has entered into a $150 million loan agreement with funds managed by Pharmakon Advisors LP, a leading global life sciences investment firm and manager of the BioPharma Credit funds. “This non-dilutive loan provides us with the financial flexibility to advance the discovery and development of potential novel treatments for sickle cell disease and other grievous blood-based conditions without diverting financial resources from the launch of our first medicine Oxbryta, which was approved by the U.S. Food and Drug Administration last month,” said Jeff Farrow, chief financial officer of GBT. The non-dilutive loan agreement provides GBT with a $150 million term loan.

  • GlobeNewswire

    GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

    Global Blood Therapeutics, Inc. (GBT) (GBT) and Syros Pharmaceuticals, Inc. (SYRS) today announced that they have entered into a collaboration to discover, develop and commercialize novel therapies for sickle cell disease (SCD) and beta thalassemia. Under the agreement, Syros will use its leading gene control platform to identify therapeutic targets and discover drugs that induce fetal hemoglobin, and GBT will receive an option to obtain an exclusive worldwide license to develop, manufacture and commercialize products resulting from the collaboration.

  • Hedge Funds Are Dumping Syros Pharmaceuticals, Inc. (SYRS)
    Insider Monkey

    Hedge Funds Are Dumping Syros Pharmaceuticals, Inc. (SYRS)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]

  • Thomson Reuters StreetEvents

    Edited Transcript of SYRS earnings conference call or presentation 12-Nov-19 1:30pm GMT

    Q3 2019 Syros Pharmaceuticals Inc Earnings Call